PACB Pacific Biosciences Of California Inc

Price (delayed)

$27.9

Market cap

$5.53B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.27

Enterprise value

$5.54B

Highlights
The EPS has grown by 21% YoY
Pacific Biosciences Of California's gross profit has increased by 17% QoQ and by 3% YoY
The company's equity fell by 16% QoQ
PACB's net income is down by 13% YoY

Key stats

What are the main financial stats of PACB
Market
Shares outstanding
198.37M
Market cap
$5.53B
Enterprise value
$5.54B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
19.2
Price to sales (P/S)
58.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60
Earnings
Revenue
$92.29M
EBIT
-$57.51M
EBITDA
-$48.17M
Free cash flow
-$80.29M
Per share
EPS
-$0.27
Free cash flow per share
-$0.41
Book value per share
$1.45
Revenue per share
$0.47
TBVPS
$6.43
Balance sheet
Total assets
$1.25B
Total liabilities
$972.34M
Debt
$936.61M
Equity
$280.55M
Working capital
$1.16B
Liquidity
Debt to equity
3.34
Current ratio
35.45
Quick ratio
34.8
Net debt/EBITDA
-0.07
Margins
EBITDA margin
-52.2%
Gross margin
41.2%
Net margin
-64.2%
Operating margin
-114.2%
Efficiency
Return on assets
-10.9%
Return on equity
-30.1%
Return on invested capital
-12.9%
Return on capital employed
-4.7%
Return on sales
-62.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PACB stock price

How has the Pacific Biosciences Of California stock price performed over time
Intraday
-0.43%
1 week
-3.96%
1 month
18.42%
1 year
654.05%
YTD
7.56%
QTD
-16.24%

Financial performance

How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$92.29M
Gross profit
$38.06M
Operating income
-$105.39M
Net income
-$59.29M
Gross margin
41.2%
Net margin
-64.2%
Pacific Biosciences Of California's gross profit has increased by 17% QoQ and by 3% YoY
The revenue has increased by 17% QoQ and by 2.5% YoY
PACB's operating margin is up by 14% since the previous quarter
PACB's net income is down by 13% YoY

Growth

What is Pacific Biosciences Of California's growth rate over time

Valuation

What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
19.2
P/S
58.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60
The EPS has grown by 21% YoY
The P/B is 109% above the 5-year quarterly average of 9.2 and 25% above the last 4 quarters average of 15.4
The company's equity fell by 16% QoQ
The price to sales (P/S) is 55% higher than the last 4 quarters average of 37.9
The revenue has increased by 17% QoQ and by 2.5% YoY

Efficiency

How efficient is Pacific Biosciences Of California business performance
The company's return on invested capital has shrunk by 170% QoQ but it has surged by 69% YoY
The ROE has soared by 65% YoY
PACB's ROA has soared by 64% YoY
The ROS has contracted by 12% YoY

Dividends

What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PACB.

Financial health

How did Pacific Biosciences Of California financials performed over time
The company's total assets is 29% higher than its total liabilities
The company's equity fell by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.